Reply to Paolo Zaurito’s Letter to the Editor re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029

Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer

10.1056/nejmoa2214122 · 2023

10.1016/j.eururo.2026.06.009

10.1016/j.eururo.2026.06.009

Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

10.1016/s0022-5347(05)66452-x · 2001

Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer

10.1056/nejmoa2403365 · 2024

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

10.1016/s0140-6736(19)31131-6 · 2019

Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B study

10.1016/j.eururo.2025.07.007 · 2026

Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score

10.1111/bju.16927 · 2026

Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial

10.1016/j.eururo.2024.08.030 · 2024